Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program
HIV Clinical Trials, 04/24/2012
Clinical Article
Lazzarin A et al. – Maraviroc plus an optimized background therapy (OBT) did not increase the incidence of AEs or severe laboratory liver abnormalities in HIV–1–infected patients coinfected with hepatitis B virus (HBV) or hepatitis C virus (HCV).



